PITTSBURGH, Jan. 29, 2026 /PRNewswire/ — MolecuLight today announced that its MolecuLightDX® wound measurement has been qualified by the U.S.…
Read More
PITTSBURGH, Jan. 29, 2026 /PRNewswire/ – MolecuLight today announced that its MolecuLightDX® wound measurement has been qualified by the U.S.…
Read More
– Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III…
Read More